Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Current Status of Pharmacokinetic Research in Children: A Systematic Review of Clinical Trial Records

Author(s): Pugazhenthan Thangaraju*, Hemasri Velmurugan and Krishnapriya Neelambaran

Volume 19, Issue 1, 2024

Published on: 11 January, 2023

Page: [78 - 92] Pages: 15

DOI: 10.2174/2772432818666221223155455

Price: $65

Abstract

Background: Many medications have different pharmacokinetics in children than in adults. Knowledge about the safety and efficacy of medications in children requires research into the pharmacokinetic profiles of children's medicines. By analysing registered clinical trial records, this study determined how frequently pharmacokinetic data is gathered in paediatric drug trials.

Methods: We searched for the pharmacokinetic data from clinical trial records for preterm infants and children up to the age of 16 from January 2011 to April 2022. The records of trials involving one or more drugs in preterm infants and children up to the age of 16 were examined for evidence that pharmacokinetic data would be collected.

Results: In a total of 1483 records of interventional clinical trials, 136 (9.17%) pharmacokinetic data involved adults. Of those 136 records, 60 (44.1%) records were pharmacokinetics trials involving one or more medicines in children up to the age of 16.20 (33.3%) in America, followed by 19 (31.6%) in Europe. Most trials researched medicines in the field of infection or parasitic diseases 20 (33.3%). 27 (48.2%) and 26 (46.4%) trials investigated medicines that were indicated as essential medicine.

Conclusion: The pharmacokinetic characteristics of children's drugs need to be better understood. The current state of pharmacokinetic research appears to address the knowledge gap in this area adequately. Despite slow progress, paediatric clinical trials have experienced a renaissance as the significance of paediatric trials has gained international attention. The outcome of paediatric trials will have an impact on children's health in the future. In recent years, the need for greater availability and access to safe child-size pharmaceuticals has received a lot of attention.

« Previous
Graphical Abstract

[1]
Godbillon J, Richard J, Gerardin A, Meinertz T, Kasper W, Jähnchen E. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981; 12(5): 621-9.
[http://dx.doi.org/10.1111/j.1365-2125.1981.tb01280.x] [PMID: 7332726]
[2]
Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 2008; 62(5): 872-8.
[http://dx.doi.org/10.1093/jac/dkn330] [PMID: 18713760]
[3]
Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J Pharmacol Exp Ther 2019; 370(3): 570-80.
[http://dx.doi.org/10.1124/jpet.119.257113] [PMID: 30837281]
[4]
White PJ, Davis EA, Santiago M, et al. Identifying the core concepts of pharmacology education. Pharmacol Res Perspect 2021; 9(4): e00836.
[http://dx.doi.org/10.1002/prp2.836] [PMID: 34288559]
[5]
Santiago M, Davis EA, Hinton T, et al. Defining and unpacking the core concepts of pharmacology education. Pharmacol Res Perspect 2021; 9(6): e00894.
[http://dx.doi.org/10.1002/prp2.894] [PMID: 34817122]
[6]
Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol 2017; 12(1): 18-25.
[http://dx.doi.org/10.2174/1574884712666170317161935] [PMID: 28322168]
[7]
Pharmacokinetics in children. MSD Manual professional version. 2020. Available from: https://www.msdmanuals.com/professional/pediatrics/principles-of-drug-treatment-in-children/pharmacokine- tics-in-children
[8]
O’Hara K. Paediatric pharmacokinetics and drug doses. Aust Prescr 2016; 39(6): 208-10.
[http://dx.doi.org/10.18773/austprescr.2016.071] [PMID: 27990048]
[9]
Drug Research and Children. The US Food and Drug Administration 2016. Available from: https://www.fda.gov/drugs/infor- mation-consumers-and-patients-drugs/drug-research-and-children
[10]
Barker CIS, Standing JF, Kelly LE, et al. Pharmacokinetic studies in children: Recommendations for practice and research. Arch Dis Child 2018; 103(7): archdischild-2017-314506.
[http://dx.doi.org/10.1136/archdischild-2017-314506] [PMID: 29674514]
[11]
World Health Organization (WHO). Available from: https://www.who.int/
[12]
Who is a child? – The Hindu. Last updated on June, 2012. Available from: https://www.thehindu.com/news/national/who-is-a-child/article3528624.ece
[13]
Food and Drug Administration. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. Rockville, MD: FDA Center for Drug Evaluation and Research 1998.
[14]
International Classification of Diseases ICD-11 Mortality and Morbidity Statistics (ICD-11 MMS). Available from: https://icd.who.int/browse11/l-m/en
[15]
WHO Model List of Essential Medicines for Children - 8th list, 2021. Last updated on 30 September 2021. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.03
[16]
National List of Essential Medicines. 2015. Available from: https://cdsco.gov.in/opencms/opencms/en/consumer/Essential-Medicines/
[17]
Centre releases NLEM 2021 with 39 additional drugs and 16 deletions from previous list. Last updated on September 4, 2021. Available from: http://www.pharmabiz.com/NewsDetails.aspx?aid=142320&sid=1
[18]
Birbeck GL, Herman ST, Capparelli EV, et al. A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria. BMC Pediatr 2019; 19(1): 399.
[http://dx.doi.org/10.1186/s12887-019-1766-2]
[19]
Su F, Nicolson SC, Zuppa AF. A dose-response study of dexmedetomidine administered as the primary sedative in infants following open heart surgery. Pediatr Crit Care Med 2013; 14(5): 499-507.
[http://dx.doi.org/10.1097/PCC.0b013e31828a8800] [PMID: 23628837]
[20]
Giugliani R, Hwu WL, Tylki-Szymanska A, Whiteman DAH, Pano A. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet Med 2014; 16(6): 435-41.
[http://dx.doi.org/10.1038/gim.2013.162] [PMID: 24202085]
[21]
Lee BH, Abdalla AF, Choi JH, et al. A multicenter, open-label, phase III study of Abcertin in Gaucher disease. Medicine 2017; 96(45): e8492.
[http://dx.doi.org/10.1097/MD.0000000000008492] [PMID: 29137040]
[22]
Khalil SN, Hahn BJ, Chumpitazi CE, Rock AD, Kaelin BA, Macias CG. A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. BMC Pediatr 2017; 17(1): 42.
[http://dx.doi.org/10.1186/s12887-017-0795-y]
[23]
Choi JH, Lee BH, Ko JM, et al. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease. J Korean Med Sci 2015; 30(4): 378-84.
[http://dx.doi.org/10.3346/jkms.2015.30.4.378] [PMID: 25829804]
[24]
Fouladi M, Perentesis JP, Wagner LM, et al. A phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: A children’s oncology group phase I consortium report. Clin Cancer Res 2015; 21(7): 1558-65.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0595] [PMID: 25467181]
[25]
Jones SA, Breen C, Heap F, et al. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab 2016; 118(3): 198-205.
[http://dx.doi.org/10.1016/j.ymgme.2016.05.006] [PMID: 27211612]
[26]
Schafer ES, Rau RE, Berg S, et al. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children’s Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 2018; 65(8): e27066.
[http://dx.doi.org/10.1002/pbc.27066] [PMID: 29719113]
[27]
Sylvester KG, Ling XB, Liu GY, et al. A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants. Gut 2014; 63(8): 1284-92.
[http://dx.doi.org/10.1136/gutjnl-2013-305130] [PMID: 24048736]
[28]
Walker S, Flume P, McNamara J, et al. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. J Cyst Fibros 2019; 18(5): 708-13.
[http://dx.doi.org/10.1016/j.jcf.2019.06.009] [PMID: 31253540]
[29]
Ward RM, Kearns GL, Tammara B, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 2011; 51(6): 876-87.
[http://dx.doi.org/10.1177/0091270010377501] [PMID: 20852004]
[30]
Baxter PA, Su JM, Onar-Thomas A, et al. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: A pediatric brain tumor consortium study. Neuro-oncol 2020; 22(6): 875-85.
[http://dx.doi.org/10.1093/neuonc/noaa016] [PMID: 32009149]
[31]
Chuk MK, Aikin A, Whitcomb T, et al. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer 2012; 59(5): 865-9.
[http://dx.doi.org/10.1002/pbc.24201] [PMID: 22847981]
[32]
Feruś K, Drabińska N, Krupa-Kozak U, Jarocka-Cyrta E. A randomized, placebo-controlled, pilot clinical trial to evaluate the effect of supplementation with prebiotic synergy 1 on iron homeostasis in children and adolescents with celiac disease treated with a gluten-free diet. Nutrients 2018; 10(11): 1818.
[http://dx.doi.org/10.3390/nu10111818] [PMID: 30469412]
[33]
Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P, Urien S. A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology 2013; 118(4): 853-62.
[http://dx.doi.org/10.1097/ALN.0b013e318283c83a] [PMID: 23343649]
[34]
Muscal JA, Thompson PA, Horton TM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A children’s oncology group phase I consortium study (ADVL0916). Pediatr Blood Cancer 2013; 60(3): 390-5.
[http://dx.doi.org/10.1002/pbc.24271] [PMID: 22887890]
[35]
Ogungbenro K, Wagner JB, Abdel-Rahman S, Leeder JS, Galetin A. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. Eur J Clin Pharmacol 2019; 75(9): 1227-35.
[http://dx.doi.org/10.1007/s00228-019-02697-y] [PMID: 31172248]
[36]
Pinto JA, Capparelli EV, Warshaw M, et al. A phase II/III trial of lopinavir/ritonavir dosed according to the WHO pediatric weight band dosing guidelines. Pediatr Infect Dis J 2018; 37(2): e29-35.
[http://dx.doi.org/10.1097/INF.0000000000001817] [PMID: 29088027]
[37]
Su JM, Thompson P, Adesina A, et al. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: A Pediatric Brain Tumor Consortium report. Neuro-oncol 2014; 16(12): 1661-8.
[http://dx.doi.org/10.1093/neuonc/nou103] [PMID: 24908656]
[38]
Ullrich NJ, Prabhu SP, Reddy AT, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: A neurofibromatosis clinical trials consortium study. Neuro-oncol 2020; 22(10): 1527-35.
[http://dx.doi.org/10.1093/neuonc/noaa071] [PMID: 32236425]
[39]
Bienert A. Bartkowska-Śniatkowska A, Wiczling P, et al. Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children. Pharmacol Rep 2013; 65(1): 107-21.
[http://dx.doi.org/10.1016/S1734-1140(13)70969-1] [PMID: 23563029]
[40]
Cressey TR, Punyawudho B, Le Coeur S, et al. Assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates. J Acquir Immune Defic Syndr 2017; 75(5): 554-60.
[http://dx.doi.org/10.1097/QAI.0000000000001447] [PMID: 28489732]
[41]
Dogterom P, Riesenberg R, de Greef R, et al. Asenapine pharmacokinetics and tolerability in a pediatric population. Drug Des Devel Ther 2018; 12: 2677-93.
[http://dx.doi.org/10.2147/DDDT.S171475]
[42]
Haller MJ, Gitelman SE, Gottlieb PA, et al. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes 2016; 65(12): 3765-75.
[http://dx.doi.org/10.2337/db16-0823] [PMID: 27669730]
[43]
Mulubwa M, Griesel HA, Mugabo P, Dippenaar R, van Wyk L. Assessment of vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates. Drugs R D 2020; 20(2): 105-13.
[http://dx.doi.org/10.1007/s40268-020-00302-7] [PMID: 32266599]
[44]
Neely M, Margol A, Fu X, et al. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother 2015; 59(6): 3090-7.
[http://dx.doi.org/10.1128/AAC.00032-15] [PMID: 25779580]
[45]
Rosenfeld M, Cunningham S, Harris WT, et al. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros 2019; 18(6): 838-43.
[http://dx.doi.org/10.1016/j.jcf.2019.03.009] [PMID: 31053538]
[46]
Sohn WY, Portale AA, Salusky IB, et al. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. Pediatr Nephrol 2019; 34(1): 145-54.
[http://dx.doi.org/10.1007/s00467-018-4054-8] [PMID: 30141180]
[47]
Viscardi RM, Othman AA, Hassan HE, et al. Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. Antimicrob Agents Chemother 2013; 57(5): 2127-33.
[http://dx.doi.org/10.1128/AAC.02183-12] [PMID: 23439637]
[48]
Cohen-Rabbie S, Mattinson A, So K, Wang N, Goldwater R. Effect of food on capsule and granule formulations of selumetinib. Clin Transl Sci 2022; 15(4): 878-88.
[http://dx.doi.org/10.1111/cts.13209] [PMID: 35170228]
[49]
Cohen-Wolkowiez M, Sampson M, Bloom BT, et al. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J 2013; 32(9): 956-61.
[http://dx.doi.org/10.1097/INF.0b013e3182947cf8] [PMID: 23587979]
[50]
Drabińska N, Krupa-Kozak U, Jarocka-Cyrta E. Intestinal permeability in children with celiac disease after the administration of oligofructose-enriched inulin into a gluten-free diet-Results of a randomized, placebo-controlled, pilot trial. Nutrients 2020; 12(6): 1736.
[http://dx.doi.org/10.3390/nu12061736] [PMID: 32531982]
[51]
Estepp JH, Wiczling P, Moen J, et al. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: Pharmacokinetics and predictive models for drug exposure. Br J Clin Pharmacol 2018; 84(7): 1478-85.
[http://dx.doi.org/10.1111/bcp.13426] [PMID: 28884840]
[52]
Fogarasi A, Flamini R, Milh M, et al. Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to < 12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures. Epilepsia 2020; 61(1): 125-37.
[http://dx.doi.org/10.1111/epi.16413] [PMID: 31912493]
[53]
Hammon K, Hart G, Vuillemenot BR, et al. Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease. Clin Transl Sci 2021; 14(5): 1810-21.
[http://dx.doi.org/10.1111/cts.13028] [PMID: 34076336]
[54]
Jiang N, Wang L, Xiang X, et al. Intracellular vincristine levels in lymphoblasts affect treatment outcome in childhood B‐lymphoblastic leukaemia: Ma‐Spore ALL 2010 study. Br J Clin Pharmacol 2021; 87(4): 1990-9.
[http://dx.doi.org/10.1111/bcp.14596] [PMID: 33037681]
[55]
Jo H, Pilla Reddy V, Parkinson J, Boulton DW, Tang W. Model‐informed pediatric dose selection for dapagliflozin by incorporating developmental changes. CPT Pharmacometrics Syst Pharmacol 2021; 10(2): 108-18.
[http://dx.doi.org/10.1002/psp4.12577] [PMID: 33439535]
[56]
Klein DJ, Battelino T, Chatterjee DJ, Jacobsen LV, Hale PM, Arslanian S. Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther 2014; 16(10): 679-87.
[http://dx.doi.org/10.1089/dia.2013.0366] [PMID: 25036533]
[57]
Lapeyraque AL, Kassir N, Théorêt Y, et al. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: A pharmacokinetic and bioequivalence study. Pediatr Nephrol 2014; 29(6): 1081-8.
[http://dx.doi.org/10.1007/s00467-013-2724-0] [PMID: 24435759]
[58]
Lutsar I, Trafojer UM, Heath PT, et al. Meropenem vs. standard of care for treatment of late onset sepsis in children of less than 90 days of age: Study protocol for a randomised controlled trial. Trials 2011; 12: 215.
[http://dx.doi.org/10.1186/1745-6215-12-215]
[59]
Marachelian A, Desai A, Balis F, et al. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol 2016; 77(2): 405-12.
[http://dx.doi.org/10.1007/s00280-015-2955-9] [PMID: 26791869]
[60]
Mudakanagoudar MS, Santhosh MC. Comparison of sevoflurane concentration for insertion of proseal laryngeal mask airway and tracheal intubation in children (correlation with BIS). Braz J Anesthesiol 2016; 66(1): 24-8.
[http://dx.doi.org/10.1016/j.bjan.2014.07.012] [PMID: 26768926]
[61]
Muntau AC, Burlina A, Eyskens F, et al. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients 4 years: Results from the SPARK open-label, multicentre, randomized phase IIIb trial. Orphanet J Rare Dis 2017; 12(1): 47.
[http://dx.doi.org/10.1186/s13023-017-0600-x]
[62]
Muntau AC, Burlina A, Eyskens F, et al. Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at  4 years of age with phenylketonuria: Results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial. Orphanet J Rare Dis 2021; 16(1): 341.
[http://dx.doi.org/10.1186/s13023-021-01968-1]
[63]
Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa K, Tanigawara Y. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. Drug Metab Pharmacokinet 2011; 26(5): 523-31.
[http://dx.doi.org/10.2133/dmpk.DMPK-11-RG-027] [PMID: 21747200]
[64]
Pariser DM, Lain EL, Mamelok RD, Drew J, Mould DR. Limited systemic exposure with topical glycopyrronium tosylate in primary axillary hyperhidrosis. Clin Pharmacokinet 2021; 60(5): 665-76.
[http://dx.doi.org/10.1007/s40262-020-00975-y] [PMID: 33433785]
[65]
Perez EE, Hébert J, Ellis AK, et al. Efficacy, safety and tolerability of a new 10% intravenous immunoglobulin for the treatment of primary immunodeficiencies. Front Immunol 2021; 12: 707463.
[http://dx.doi.org/10.3389/fimmu.2021.707463]
[66]
Petit C, Jullien V, Samson A, et al. Designing a pediatric study for an antimalarial drug by using information from adults. Antimicrob Agents Chemother 2015; 60(3): 1481-91.
[http://dx.doi.org/10.1128/AAC.01125-15]
[67]
Ratjen F, Durham T, Navratil T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012; 11(6): 539-49.
[http://dx.doi.org/10.1016/j.jcf.2012.05.003] [PMID: 22682898]
[68]
Rosenfeld M, Wainwright CE, Higgins M, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to < 24 months and with a CFTR gating mutation (ARRIVAL): A phase 3 single-arm study. Lancet Respir Med 2018; 6(7): 545-53.
[http://dx.doi.org/10.1016/S2213-2600(18)30202-9] [PMID: 29886024]
[69]
Sagel SD, Sontag MK, Anthony MM, Emmett P, Papas KA. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst Fibros 2011; 10(1): 31-6.
[http://dx.doi.org/10.1016/j.jcf.2010.09.005] [PMID: 20961818]
[70]
Sassen SDT, Mathôt RAA, Pieters R, et al. Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to dutch childhood oncology group protocols and its relation to treatment response. Br J Haematol 2021; 194(2): 423-32.
[http://dx.doi.org/10.1111/bjh.17572] [PMID: 34060065]
[71]
Schmitz ML, Blumer JL, Cetnarowski W, Rubino CM. Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years. Antimicrob Agents Chemother 2015; 59(7): 4173-80.
[http://dx.doi.org/10.1128/AAC.00082-15] [PMID: 25941220]
[72]
Schoemaker R, Wade JR, Stockis A. Extrapolation of a brivaracetam exposure-response model from adults to children with focal seizures. Clin Pharmacokinet 2018; 57(7): 843-54.
[http://dx.doi.org/10.1007/s40262-017-0597-2] [PMID: 28884437]
[73]
Shakhnovich V, Abdel-Rahman S, Friesen CA, et al. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Pediatr Obes 2019; 14(1): e12459.
[http://dx.doi.org/10.1111/ijpo.12459]
[74]
Veal GJ, Cole M, Chinnaswamy G, et al. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur J Cancer 2016; 55: 56-64.
[http://dx.doi.org/10.1016/j.ejca.2015.12.007] [PMID: 26773420]
[75]
Willmann S, Becker C, Burghaus R, et al. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet 2014; 53(1): 89-102.
[http://dx.doi.org/10.1007/s40262-013-0090-5] [PMID: 23912563]
[76]
Abbas R, Park G, Damle B, Chertkoff R, Alon S. Pharmacokinetics of novel plant cell-expressed taliglucerase alfa in adult and pediatric patients with gaucher disease. PLoS One 2015; 10(6): e0128986.
[http://dx.doi.org/10.1371/journal.pone.0128986]
[77]
Baverel PG, Jain M, Stelmach I, et al. Pharmacokinetics of tralokinumab in adolescents with asthma: Implications for future dosing. Br J Clin Pharmacol 2015; 80(6): 1337-49.
[http://dx.doi.org/10.1111/bcp.12725] [PMID: 26182954]
[78]
Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised who-recommended treatment guidelines. Antimicrob Agents Chemother 2016; 60(4): 2171-9.
[http://dx.doi.org/10.1128/AAC.02600-15]
[79]
Berkun Y, Wason S, Brik R, et al. Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever. Int J Immunopathol Pharmacol 2012; 25(4): 1121-30.
[http://dx.doi.org/10.1177/039463201202500429] [PMID: 23298502]
[80]
Chokephaibulkit K, Cressey TR, Capparelli E, et al. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir Ther 2011; 16(8): 1287-95.
[http://dx.doi.org/10.3851/IMP1931] [PMID: 22155910]
[81]
Findling RL, Robb AS, DelBello M, et al. Pharmacokinetics and safety of vortioxetine in pediatric patients. J Child Adolesc Psychopharmacol 2017; 27(6): 526-34.
[http://dx.doi.org/10.1089/cap.2016.0155] [PMID: 28333546]
[82]
Gertler R, Gruber M, Grassin-Delyle S, et al. Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery. Br J Clin Pharmacol 2017; 83(8): 1745-57.
[http://dx.doi.org/10.1111/bcp.13274] [PMID: 28245519]
[83]
Ghezzi A, Comi G, Grimaldi LM, et al. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurol Neuroimmunol Neuroinflamm 2019; 6(5): e591.
[http://dx.doi.org/10.1212/NXI.0000000000000591] [PMID: 31355324]
[84]
Ivaturi V, Dvorak CC, Chan D, et al. Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2017; 23(10): 1701-13.
[http://dx.doi.org/10.1016/j.bbmt.2017.06.021] [PMID: 28684371]
[85]
Leroux S, Jacqz-Aigrain E, Elie V, et al. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: A randomized, open-label clinical trial. Br J Clin Pharmacol 2018; 84(9): 1989-99.
[http://dx.doi.org/10.1111/bcp.13628] [PMID: 29744900]
[86]
Martinón-Torres F, Rusch S, Huntjens D, et al. Pharmacokinetics, safety, and antiviral effects of multiple doses of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: A randomized phase 1b study. Clin Infect Dis 2020; 71(10): e594-603.
[http://dx.doi.org/10.1093/cid/ciaa283] [PMID: 32201897]
[87]
Merchan LM, Hassan HE, Terrin ML, et al. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. Antimicrob Agents Chemother 2015; 59(1): 570-8.
[http://dx.doi.org/10.1128/AAC.03951-14] [PMID: 25385115]
[88]
Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. J Pediatric Infect Dis Soc 2015; 4(4): e76-83.
[http://dx.doi.org/10.1093/jpids/piu146] [PMID: 26582887]
[89]
Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 2014; 58(3): 413-22.
[http://dx.doi.org/10.1093/cid/cit696] [PMID: 24145879]
[90]
Nacro B, Zoure E, Hien H, et al. Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial. Bull World Health Organ 2011; 89(6): 451-8.
[http://dx.doi.org/10.2471/BLT.10.081646] [PMID: 21673861]
[91]
Nakamura H, Kawashima H, Azuma R, Sato I, Nagao K, Miyazawa K. Pharmacokinetics of the H(2) blocker roxatidine acetate hydrochloride in pediatric patients, in comparison with healthy adult volunteers. Drug Metab Pharmacokinet 2012; 27(4): 422-9.
[http://dx.doi.org/10.2133/dmpk.DMPK-11-RG-112] [PMID: 22293541]
[92]
Rubino CM, Polak M, Schröpf S, et al. Pharmacokinetics and safety of ceftobiprole in pediatric patients. Pediatr Infect Dis J 2021; 40(11): 997-1003.
[http://dx.doi.org/10.1097/INF.0000000000003296] [PMID: 34533489]
[93]
Schmitz ML, Rubino CM, Onufrak NJ, et al. Pharmacokinetics and optimal dose selection of cefazolin for surgical prophylaxis of pediatric patients. J Clin Pharmacol 2021; 61(5): 666-76.
[http://dx.doi.org/10.1002/jcph.1785] [PMID: 33202066]
[94]
Schulz JD, Coulibaly JT, Schindler C, Wimmersberger D, Keiser J. Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. J Antimicrob Chemother 2019; 74(6): 1642-7.
[http://dx.doi.org/10.1093/jac/dkz083] [PMID: 30859185]
[95]
Smith MJ, Gonzalez D, Goldman JL, et al. Pharmacokinetics of clindamycin in obese and nonobese children. Antimicrob Agents Chemother 2017; 61(4): e02014-6.
[http://dx.doi.org/10.1128/AAC.02014-16]
[96]
Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr 2016; 72(3): 289-96.
[http://dx.doi.org/10.1097/QAI.0000000000000968] [PMID: 26918544]
[97]
Tsai M, Nery ESM, Kerr L, et al. Pharmacokinetics, safety, and tolerability of lasmiditan in pediatric patients with migraine. Clin Pharmacokinet 2021; 60(6): 819-28.
[http://dx.doi.org/10.1007/s40262-020-00966-z] [PMID: 33565026]
[98]
Velzen AJ, Uges JWF, Heijerman HGM, et al. Pharmacokinetics and safety of tobramycin nebulization with the I‐neb and PARI‐LC Plus in children with cystic fibrosis: A randomized, crossover study. Br J Clin Pharmacol 2019; 85(9): 1984-93.
[http://dx.doi.org/10.1111/bcp.13988] [PMID: 31112621]
[99]
Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011; 118(18): 4985-91.
[http://dx.doi.org/10.1182/blood-2011-07-364190] [PMID: 21876119]
[100]
Watt KM, Hornik CP, Balevic SJ, et al. Pharmacokinetics of ticarcillin-clavulanate in premature infants. Br J Clin Pharmacol 2019; 85(5): 1021-7.
[http://dx.doi.org/10.1111/bcp.13882] [PMID: 30710387]
[101]
Akshintala S, Marcus L, Warren KE, et al. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatr Blood Cancer 2015; 62(4): 603-10.
[http://dx.doi.org/10.1002/pbc.25344] [PMID: 25556988]
[102]
Alexander TB, Lacayo NJ, Choi JK, et al. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J Clin Oncol 2016; 34(34): 4094-101.
[http://dx.doi.org/10.1200/JCO.2016.67.5066] [PMID: 27507877]
[103]
Ali AM, Penny MA, Smith TA, et al. Population pharmacokinetics of the antimalarial amodiaquine: A pooled analysis to optimize dosing. Antimicrob Agents Chemother 2018; 62(10): e02193-217.
[http://dx.doi.org/10.1128/AAC.02193-17]
[104]
Altcheh J, Moscatelli G, Mastrantonio G, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 2014; 8(5): e2907.
[http://dx.doi.org/10.1371/journal.pntd.0002907]
[105]
An G, Ohls RK, Christensen RD, Widness JA, Mock DM, Veng-Pedersen P. Population pharmacokinetics of darbepoetin in infants following single intravenous and subcutaneous dosing. J Pharm Sci 2017; 106(6): 1644-9.
[http://dx.doi.org/10.1016/j.xphs.2017.02.001] [PMID: 28189627]
[106]
Ayyoub A, Methaneethorn J, Ramharter M, et al. Population pharmacokinetics of pyronaridine in pediatric malaria patients. Antimicrob Agents Chemother 2015; 60(3): 1450-8.
[http://dx.doi.org/10.1128/AAC.02004-15]
[107]
Bagchus WM, Bezuidenhout D, Harrison-Moench E, Kourany-Lefoll E, Wolna P, Yalkinoglu O. Relative bioavailability of orally dispersible tablet formulations of Levo and racemic praziquantel: Two phase I studies. Clin Transl Sci 2019; 12(1): 66-76.
[http://dx.doi.org/10.1111/cts.12601] [PMID: 30536632]
[108]
Bellanti F, Del Vecchio GC, Putti MC, et al. Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years. Br J Clin Pharmacol 2017; 83(3): 593-602.
[http://dx.doi.org/10.1111/bcp.13134] [PMID: 27641003]
[109]
Bestebreurtje P, de Koning BAE, Roeleveld N, et al. Rectal omeprazole in infants with gastroesophageal reflux disease: A randomized pilot trial. Eur J Drug Metab Pharmacokinet 2020; 45(5): 635-43.
[http://dx.doi.org/10.1007/s13318-020-00630-8] [PMID: 32594305]
[110]
Clements JD, Zhu M, Kuchimanchi M, Terminello B, Doshi S. Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies. Clin Pharmacokinet 2020; 59(4): 463-74.
[http://dx.doi.org/10.1007/s40262-019-00823-8] [PMID: 31679130]
[111]
Cohen-Wolkowiez M, Benjamin DK Jr, Ross A, et al. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit 2012; 34(3): 312-9.
[http://dx.doi.org/10.1097/FTD.0b013e3182587665] [PMID: 22569355]
[112]
Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: A pilot randomized controlled trial. Am J Obstet Gynecol 2016; 214(6): 720.e1-720.e17.
[http://dx.doi.org/10.1016/j.ajog.2015.12.038] [PMID: 26723196]
[113]
Dong L, Zhai XY, Yang YL, et al. Population pharmacokinetics and dosing optimization of imipenem in children with hematological malignancies. Antimicrob Agents Chemother 2019; 63(6): e00006-19.
[http://dx.doi.org/10.1128/AAC.00006-19]
[114]
Gonzalez D, Chamberlain JM, Guptill JT, et al. Population pharmacokinetics and exploratory pharmacodynamics of lorazepam in pediatric status epilepticus. Clin Pharmacokinet 2017; 56(8): 941-51.
[http://dx.doi.org/10.1007/s40262-016-0486-0] [PMID: 27943220]
[115]
Greenberg RG, Wu H, Laughon M, et al. Population pharmacokinetics of dexmedetomidine in infants. J Clin Pharmacol 2017; 57(9): 1174-82.
[http://dx.doi.org/10.1002/jcph.904] [PMID: 28444697]
[116]
Guidi M, Mercier T, Aouri M, et al. Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children. Malar J 2019; 18(1): 139.
[http://dx.doi.org/10.1186/s12936-019-2754-6]
[117]
Hanley MJ, Mould DR, Taylor TJ, et al. Population pharmacokinetic analysis of bortezomib in pediatric leukemia patients: Model-based support for body surface area-based dosing over the 2- to 16-year age range. J Clin Pharmacol 2017; 57(9): 1183-93.
[http://dx.doi.org/10.1002/jcph.906] [PMID: 28419486]
[118]
Hope WW, Kaibara A, Roy M, et al. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. Antimicrob Agents Chemother 2015; 59(2): 905-13.
[http://dx.doi.org/10.1128/AAC.03736-14] [PMID: 25421470]
[119]
Jacobo-Cabral CO, García-Roca P, Romero-Tejeda EM, et al. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: Role of CYP3A5 genotype and formulation. Br J Clin Pharmacol 2015; 80(4): 630-41.
[http://dx.doi.org/10.1111/bcp.12649] [PMID: 25846845]
[120]
Ku LC, Hornik CP, Beechinor RJ, et al. Population pharmacokinetics and exploratory exposure-response relationships of diazepam in children treated for status epilepticus. CPT Pharmacometrics Syst Pharmacol 2018; 7(11): 718-27.
[http://dx.doi.org/10.1002/psp4.12349] [PMID: 30267478]
[121]
Lulla RR, Goldman S, Yamada T, et al. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A pediatric brain tumor consortium study. Neuro-oncol 2016; 18(9): 1319-25.
[http://dx.doi.org/10.1093/neuonc/now047] [PMID: 27022131]
[122]
Mann D, Liu J, Chew ML, et al. Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: A phase 1, randomized controlled study. Epilepsia 2014; 55(12): 1934-43.
[http://dx.doi.org/10.1111/epi.12830] [PMID: 25377429]
[123]
Marçon F, Guittet C, Manso MA, et al. Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin. Eur J Pharm Sci 2018; 114: 46-54.
[http://dx.doi.org/10.1016/j.ejps.2017.11.030] [PMID: 29203151]
[124]
Prémaud A, Weber LT, Tönshoff B, et al. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol Res 2011; 63(3): 216-24.
[http://dx.doi.org/10.1016/j.phrs.2010.10.017] [PMID: 21056671]
[125]
Ramos-Martín V, Neely MN, McGowan P, et al. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. J Antimicrob Chemother 2016; 71(11): 3168-78.
[http://dx.doi.org/10.1093/jac/dkw295] [PMID: 27543654]
[126]
Ramos-Martín V, Paulus S, Siner S, et al. Population pharmacokinetics of teicoplanin in children. Antimicrob Agents Chemother 2014; 58(11): 6920-7.
[http://dx.doi.org/10.1128/AAC.03685-14] [PMID: 25224001]
[127]
Ricotti V, Spinty S, Roper H, et al. Safety, tolerability, and pharmacokinetics of smt c1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with duchenne muscular dystrophy. PLoS One 2016; 11(4): e0152840.
[http://dx.doi.org/10.1371/journal.pone.0152840]
[128]
Roberts JK, Birg AV, Lin T, et al. Population pharmacokinetics of oral topotecan in infants and very young children with brain tumors demonstrates a role of ABCG2 rs4148157 on the absorption rate constant. Drug Metab Dispos 2016; 44(7): 1116-22.
[http://dx.doi.org/10.1124/dmd.115.068676] [PMID: 27052877]
[129]
Seibel NL, Shad AT, Bekersky I, et al. Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients. Antimicrob Agents Chemother 2017; 61(2): e01477-516.
[http://dx.doi.org/10.1128/AAC.01477-16]
[130]
Sidharta PN. Štěpánová R, Globig S, Ulč I, Csonka D. Relative bioavailability of a pediatric dispersible tablet and adult film‐coated tablet of macitentan in healthy volunteers. Pharmacol Res Perspect 2020; 8(2): e00580.
[http://dx.doi.org/10.1002/prp2.580] [PMID: 32302056]
[131]
Stricker PA, Gastonguay MR, Singh D, et al. Population pharmacokinetics of ε-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery. Br J Anaesth 2015; 114(4): 689-99.
[http://dx.doi.org/10.1093/bja/aeu459] [PMID: 25586726]
[132]
Su JM, Li XN, Thompson P, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A children’s oncology group report. Clin Cancer Res 2011; 17(3): 589-97.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-0738] [PMID: 21115653]
[133]
Teramoto T, Matsui E, Fukao T, et al. Repeated-dose pharmacokinetics of inhaled ciclesonide (CIC-HFA) in japanese children with bronchial asthma: A phase I study. Allergology international. Official Journal of the Japanese Society of Allergology 2012; 61(4): 619-24.
[134]
Turner DC, Navid F, Daw NC, et al. Population pharmacokinetics of bevacizumab in children with osteosarcoma: Implications for dosing. Clin Cancer Res 2014; 20(10): 2783-92.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-2364] [PMID: 24637635]
[135]
Wang A, Cui C, Fan Y, et al. Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: A prospective randomized controlled trial. Crit Care 2019; 23(1): 428.
[http://dx.doi.org/10.1186/s13054-019-2704-2]
[136]
Wang H, Jones AK, Dvorak CC, et al. Population pharmacokinetics of clofarabine as part of pretransplantation conditioning in pediatric subjects before hematopoietic cell transplantation. Biol Blood Marrow Transplant 2019; 25(8): 1603-10.
[http://dx.doi.org/10.1016/j.bbmt.2019.04.017] [PMID: 31002993]
[137]
Wasserman RL, Church JA, Stein M, et al. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. J Clin Immunol 2012; 32(4): 663-9.
[http://dx.doi.org/10.1007/s10875-012-9656-5] [PMID: 22392046]
[138]
Williams JH, Jayaraman B, Swoboda KJ, Barrett JS. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J Clin Pharmacol 2012; 52(11): 1676-88.
[http://dx.doi.org/10.1177/0091270011428138] [PMID: 22167565]
[139]
Würthwein G, Lanvers-Kaminsky C, Siebel C, et al. Population pharmacokinetics of PEGylated asparaginase in children with acute lymphoblastic leukemia: Treatment phase dependency and predictivity in case of missing data. Eur J Drug Metab Pharmacokinet 2021; 46(2): 289-300.
[http://dx.doi.org/10.1007/s13318-021-00670-8] [PMID: 33595793]
[140]
Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation. J Thromb Haemost 2020; 18(7): 1672-85.
[http://dx.doi.org/10.1111/jth.14813] [PMID: 32246743]
[141]
Zhao W, Zhang D, Storme T, Baruchel A, Declèves X, Jacqz-Aigrain E. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease. Br J Clin Pharmacol 2015; 80(5): 1197-207.
[http://dx.doi.org/10.1111/bcp.12710] [PMID: 26138279]
[142]
Cella M, Knibbe C, de Wildt SN, Van Gerven J, Danhof M, Della Pasqua O. Scaling of pharmacokinetics across paediatric populations: The lack of interpolative power of allometric models. Br J Clin Pharmacol 2012; 74(3): 525-35.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04206.x] [PMID: 22300419]
[143]
Dobson NR, Liu X, Rhein LM, et al. Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy. Br J Clin Pharmacol 2016; 82(3): 754-61.
[http://dx.doi.org/10.1111/bcp.13001] [PMID: 27145974]
[144]
DuBois SG, Shusterman S, Reid JM, et al. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: A children’s oncology group study. Cancer Chemother Pharmacol 2012; 69(4): 1021-7.
[http://dx.doi.org/10.1007/s00280-011-1798-2] [PMID: 22179104]
[145]
El-Lahony DM, Saleh NY, Habib MS, Shehata MA, El-Hawy MA. The role of recombinant Human erythropoietin in neonatal anemia. Hematol Oncol Stem Cell Ther 2020; 13(3): 147-51.
[http://dx.doi.org/10.1016/j.hemonc.2019.08.004] [PMID: 31628923]
[146]
Gastine S, Obiero C, Kane Z, et al. Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis. J Antimicrob Chemother 2022; 77(2): 448-56.
[http://dx.doi.org/10.1093/jac/dkab413] [PMID: 35107141]
[147]
Hill KD, Tunks RD, Barker PCA, et al. Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med 2013; 14(6): 593-600.
[http://dx.doi.org/10.1097/PCC.0b013e31828aa5ee] [PMID: 23823195]
[148]
King JR, Yogev R, Jean-Philippe P, et al. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Antimicrob Agents Chemother 2011; 55(9): 4290-4.
[http://dx.doi.org/10.1128/AAC.01334-10] [PMID: 21670182]
[149]
Mooij MG, van Duijn E, Knibbe CAJ, et al. Successful use of [14C]paracetamol microdosing to elucidate developmental changes in drug metabolism. Clin Pharmacokinet 2017; 56(10): 1185-95.
[http://dx.doi.org/10.1007/s40262-017-0508-6] [PMID: 28155137]
[150]
Nemecek ER, Hilger RA, Adams A, et al. Treosulfan, fludarabine, and low-dose total body irradiation for children and young adults with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation: Prospective phase II trial of the pediatric blood and marrow transplant consortium. Biol Blood Marrow Transplant 2018; 24(8): 1651-6.
[http://dx.doi.org/10.1016/j.bbmt.2018.04.025] [PMID: 29753157]
[151]
Oliver A, VanBuren S, Allen A, et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clin Ther 2014; 36(6): 928-939.e1.
[http://dx.doi.org/10.1016/j.clinthera.2014.03.014] [PMID: 24793536]
[152]
Plyku D, Loeb DM, Prideaux AR, et al. Strengths and weaknesses of a planar whole-body method of 153Sm dosimetry for patients with metastatic osteosarcoma and comparison with three-dimensional dosimetry. Cancer Biother Radiopharm 2015; 30(9): 369-79.
[http://dx.doi.org/10.1089/cbr.2014.1803] [PMID: 26560193]
[153]
Azarbar S, Salardini A, Dahdah N, et al. A phase I-II, open-label, multicenter trial to determine the dosimetry and safety of 99mTc-Sestamibi in pediatric subjects. J Nucl Med 2015; 56(5): 728-36.
[http://dx.doi.org/10.2967/jnumed.114.146795] [PMID: 25858045]
[154]
Viergever RF, Rademaker CM, Ghersi D. Pharmacokinetic research in children: An analysis of registered records of clinical trials. BMJ Open 2011; 1(1): e000221.
[http://dx.doi.org/10.1136/bmjopen-2011-000221]
[155]
Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J Clin Pharmacol 2015; 79(3): 357-69.
[http://dx.doi.org/10.1111/bcp.12305] [PMID: 24325152]
[156]
Mahmood I. Prediction of drug clearance in children from adults: A comparison of several allometric methods. Br J Clin Pharmacol 2006; 61(5): 545-57.
[http://dx.doi.org/10.1111/j.1365-2125.2006.02622.x] [PMID: 16669848]
[157]
Stephenson T. How children’s responses to drugs differ from adults. Br J Clin Pharmacol 2005; 59(6): 670-3.
[http://dx.doi.org/10.1111/j.1365-2125.2005.02445.x] [PMID: 15948930]
[158]
Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics 2011; 3(1): 53-72.
[http://dx.doi.org/10.3390/pharmaceutics3010053]
[159]
Cresteil T. Onset of xenobiotic metabolism in children: Toxicological implications. Food Addit Contam 1998; 15: 45-51.
[http://dx.doi.org/10.1080/02652039809374614] [PMID: 9602911]
[160]
Food and Drug Administration. Ontogeny of Transporter Function 2019. Available from: https://www.fda.gov/media/128353/download
[161]
Vermeulen E, van den Anker JN, Della Pasqua O, Hoppu K, van der Lee JH. How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians. J Pharm Pharmacol 2017; 69(4): 439-47.
[http://dx.doi.org/10.1111/jphp.12637] [PMID: 27671925]
[162]
Baber N, Pritchard D. Dose estimation for children. Br J Clin Pharmacol 2003; 56(5): 489-93.
[http://dx.doi.org/10.1046/j.1365-2125.2003.01901.x] [PMID: 14651721]
[163]
De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67 (Suppl. 1): 5-16.
[http://dx.doi.org/10.1007/s00228-009-0782-9]
[164]
Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med 2005; 10: 115e22.
[http://dx.doi.org/10.1016/j.siny.2004.11.003]
[165]
Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F142-4.
[http://dx.doi.org/10.1136/fn.80.2.F142]
[166]
Allen HC, Garbe MC, Lees J, et al. Off-label medication use in children, more common than we think: A systematic review of the literature. J Okla State Med Assoc 2018; 111(8): 776-83.
[PMID: 31379392]
[167]
Kenyon EM, Lipscomb JC, Pegram RA, George BJ, Hines RN. The impact of scaling factor variability on risk-relevant pharmacokinetic outcomes in children: A case study using bromodichloromethane (BDCM). Toxicol Sci 2019; 167(2): 347-59.
[http://dx.doi.org/10.1093/toxsci/kfy236] [PMID: 30252107]
[168]
Saida K, Fukuda T, Mizuno K, Ogura M, Kamei K, Ito S. Pharmacokinetics and pharmacodynamics estimation of eculizumab in a 2-year-old girl with atypical hemolytic uremic syndrome: A case report with 4-year follow-up. Front Pediatr 2019; 7: 519.
[http://dx.doi.org/10.3389/fped.2019.00519] [PMID: 31921730]
[169]
Connor EM, Smoyer WE, Davis JM, et al. Meeting the demand for pediatric clinical trials. Sci Transl Med 2014; 6(227): 227fs11.
[http://dx.doi.org/10.1126/scitranslmed.3008043] [PMID: 24622511]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy